In this issue:
Watch-and-wait strategy for rectal cancer
In mCRC
No survival benefit with atezolizumab
Real-world treatment patterns in Australia
Third-line rechallenge with cetuximab and irinotecan
Continuation of bevacizumab second-line
Response to HER2-targeted therapy
Triplet therapy with binimetinib, encorafenib + cetuximab
Sequential escalation therapy vs upfront combination
Checkpoint blockade not costeffective
Comparing mutation detection thresholds
Please login below to download this issue (PDF)